Tejas Savant
Stock Analyst at Morgan Stanley
(2.31)
# 2,688
Out of 5,005 analysts
233
Total ratings
42.42%
Success rate
-1.66%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Overweight | $65 → $68 | $91.66 | -25.81% | 4 | Aug 12, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $18 → $17 | $12.75 | +33.33% | 15 | Aug 12, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $100 → $105 | $102.12 | +2.82% | 9 | Aug 4, 2025 | |
| AVTR Avantor | Maintains: Equal-Weight | $15 → $12 | $14.29 | -16.03% | 20 | Aug 4, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $65 → $69 | $68.22 | +1.14% | 10 | Jul 31, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $10 → $8 | $9.10 | -12.09% | 14 | Jul 30, 2025 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $3.97 | +76.32% | 9 | May 28, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $9.68 | -27.69% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $14.38 | -37.41% | 12 | May 5, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $3.09 | +61.81% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $65.55 | -69.49% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $167.35 | +10.55% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $206.63 | +20.99% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $543.32 | +24.79% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $25.98 | -11.47% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $36.00 | -22.22% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $8.06 | +160.55% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.49 | +34.23% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $16.14 | +147.83% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.88 | +579.81% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.40 | +127.27% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.79 | -27.44% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $7.34 | -31.88% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.28 | +338.60% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $62.84 | +16.17% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $177.33 | +40.98% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $7.74 | +1,191.99% | 5 | May 12, 2022 |
Tempus AI
Aug 12, 2025
Maintains: Overweight
Price Target: $65 → $68
Current: $91.66
Upside: -25.81%
10x Genomics
Aug 12, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $12.75
Upside: +33.33%
Illumina
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $102.12
Upside: +2.82%
Avantor
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $14.29
Upside: -16.03%
Hologic
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $65 → $69
Current: $68.22
Upside: +1.14%
NeoGenomics
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $9.10
Upside: -12.09%
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.97
Upside: +76.32%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $9.68
Upside: -27.69%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $14.38
Upside: -37.41%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.09
Upside: +61.81%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $65.55
Upside: -69.49%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $167.35
Upside: +10.55%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $206.63
Upside: +20.99%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $543.32
Upside: +24.79%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $25.98
Upside: -11.47%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $36.00
Upside: -22.22%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $8.06
Upside: +160.55%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.49
Upside: +34.23%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $16.14
Upside: +147.83%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.88
Upside: +579.81%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.40
Upside: +127.27%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.79
Upside: -27.44%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $7.34
Upside: -31.88%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.28
Upside: +338.60%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $62.84
Upside: +16.17%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $177.33
Upside: +40.98%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $7.74
Upside: +1,191.99%